



Subject	Group, Disease	Age	Sex	Race/ Ethnicity	Related FH	Other Auto-immune	Duration of Disease
1	Screening, Active	45	F	White	Negative	None	13
2	Screening, Active	52	M	Asian	Negative	None	37+
3	Screening, Active	30	F	White	Negative	None	23
4	Screening, Active	44	F	White/ Hispanic	Negative	None	34
5	Screening, Active	34	F	White	Negative	None	10+
6	Screening, Active	30	F	Black/ Hispanic	Negative	None	2
7	Screening, Active	34	F	Black/ Hispanic	Negative	None	4
8	Screening, Active	52	M	White	Negative	None	34+
9	Validation, Stable	39	M	White	Negative	None	15+
10	Validation, Stable	47	F	White	Negative	None	30+
11	Validation, Active	55	F	White	Negative	None	2
12	Validation, Stable	31	F	White	Negative	None	25
13	Validation, Active	62	F	Black	Negative	Hashimoto's Thyroiditis	1
14	Validation, Active	49	F	White	Negative	None	19
15	Validation, Active	54	F	Black	Negative	None	7
16	Validation, Active	8	F	Asian	Negative	None	5
17	Validation, Active	56	F	White	Negative	None	41
18	Validation, Active	51	F	White	Vitiligo	None	37
19	Validation, Stable	33	M	White	Negative	None	7
20	Validation, Active	55	M	White	RA	None	5
21	Screening, Healthy	61	F	White	Type 1 Diabetes	None	N/A

22	Screening, Healthy	25	F	Black	Negative	None	N/A
23	Screening, Healthy	25	F	Black	Negative	None	N/A
24	Screening, Healthy	18	F	White/ Hispanic	Vitiligo	None	N/A
25	Screening, Healthy	24	M	White	Negative	None	N/A
26	Screening, Healthy	28	F	White	Negative	None	N/A
27	Screening, Healthy	25	M	White	Negative	None	N/A
28	Screening, Healthy	33	M	White	Negative	None	N/A
29	Validation, Healthy	40	F	Asian	Vitiligo	None	N/A


Supplementary Figure 1: Gating Strategy and Flow Controls



Supplementary Figure 2: CD3 and CD4 Quantification



Supplementary Figure 3: Skin CXCL11 and IFN-g Protein Concentration



Supplementary Figure 1: Gating Strategy and Flow Controls:

A: CD8⁺ and CD4⁺ cells were gated in the following manner: singlets, cell gate, live cells by dead stain exclusion, all CD45⁺ cells and all T cells (CD3⁺ cells). B: Whole stained blood was used to make FMOs to draw the CXCR3 gate.

Supplementary Figure 2: CD3 and CD4 Quantification

A-C: Quantification of CD3 and CD4 positive cells normalized to CD45⁺ cells in the skin of vitiligo subjects and healthy controls. Results are shown separately for the Defining Group (A) and Validation Group (B), as well as both data sets combined (C).

D: ROC analysis of compiled CD3 counts from both groups. Red dot signifies a threshold value 6927 normalized CD3 T cells which achieves a sensitivity of 81.4% and specificity of 75.5%.

Supplementary Figure 3: Skin CXCL11 and IFN-g Protein Concentration

A-B: Quantification of CXCL11 (A) and IFN-g (B) protein concentration by ELISA of blister fluid in vitiligo subjects and healthy controls.

Supplementary Table 1: Subject demographic information

+ signifies that the subject had vitiligo for at least the number of indicated years.